Session

Improvement in the management of non muscle-invasive bladder cancer

Poster Session 17

  • Location:
    Room 14b (ICM, Level 1)
  • Chairs:
     M. Babjuk, Prague (CZ)
     P. Gontero, Turin (IT)
     G. Simone, Rome (IT)
  • Aims and objectives of this session

    After primary transurethral resection of the bladder tumour (TURBT), adjuvant intravesical instillations are most commonly used to manage intermediate – high risk NMIBC. However, whether a preventive radical cystectomy (RC) should be performed in selected cases of high-grade T1 remains a moot point. The purpose of the session is to discuss current strategies according to recognised challenges in the field: increase the detection of bladder cancer and flat lesions, reduce residual tumours, reduce recurrence rate, prolongation of follow-up cystoscopies.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
* 203
Modelling the burden of bladder cancer and monitoring cystoscopies in Europe

By: Vecino Ortiz A.I., Glover R., Adams E.J.

Institutes: Aquarius Population Health, Health Economics, London, United Kingdom

204
Randomized controlled study of the efficacy and safety of continuous saline bladder irrigation after transurethral resection for the treatment of non-muscle invasive bladder cancer

By: Onishi T.1, Sibahara T.1, Masui S.1, Sugino Y.1, Sasaki T.2

Institutes: 1Ise Red Cress Hospital, Dept. of Urology, Ise, Japan, 2Mie University Hospital, Dept. of Urology, Tsu, Japan

205
Intravesical Bacillus Calmette-Guérin (BCG) versus combination of epirubicin and interferon-α2a (EPI+INF) instillations in prevention of frequently recurrent non-muscle-invasive bladder carcinoma (NMIBC) - FinnBladder-6 study

By: Marttila T.2, Järvinen R.1, Seppänen M.3, Liukkonen T.4, Raitanen M.2, Boström P.5, Kaasinen E.6

Institutes: 1Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, 2Seinäjoki Central Hospital, Dept. of Urology, Seinäjoki, Finland, 3Satakunta Central Hospital, Dept. of Urology, Pori, Finland, 4Mikkeli Central Hospital, Dept. of Urology, Mikkeli, Finland, 5Turku University Hospital, Dept. of Urology, Turku, Finland, 6Hyvinkää Hospital, Dept. of Urology, Hyvinkää, Finland

206
Cancer-specific survival in patients with primary bladder CIS

By: Jancke G.

Institutes: Skånes Universitetssjukhus, Dept. of Urology, Malmö, Sweden

207
3rd course of BCG instillation to the patients with primary CIS of bladder: Is it safe?

By: Kim S.J.1, Hong S.2, Kim H.J.2, You D.1, Jeong I.G.1, Song C.1, Hong B.S.1, Kim C.S.1, Ahn H.1, Hong J.H.1

Institutes: 1Asan Medical Center, Dept. of Urology, Seoul, South Korea, 2Dankook University College of Medicine, Dept. of Urology, Cheonan, South Korea

* 208
Transurethral resection guided by photodynamic diagnosis can prevent progression in non-muscle invasive bladder cancer patients

By: Rolevich A.I.1, Zhegalik A.G.1, Minich A.A.1, Nabebina T.I.2, Polyakov S.A.1, Krasny S.A.1, Sukonko O.G.1

Institutes: 1N.N. Alexandrov National Cancer Centre of Belarus, Dept. of Urology, Minsk, Belarus, 2N.N. Alexandrov National Cancer Centre of Belarus, Dept. of Pathology, Minsk, Belarus

209
A phase 1 clinical trial assessing an intravesical administered second-generation antisense oligonucleotide targeting heat shock protein 27 in bladder cancer

By: Frees S., Beraldi E., Chi K., Fazli L., Black P., Gleave M., So A.

Institutes: Vancouver Prostate Centre, Dept. of Urological Sciences, Vancouver, Canada

210
Randomized study of intravesical chemotherapy using pirarubicin in low- and intermediate risk non-muscle-invasive bladder cancer in Japan - comparison one immediate postoperative intravesical chemotherapy with short-term adjuvant intravesical chemotherapy after TURBT

By: Naya Y.1, Shiraishi T.1, Oishi M.1, Ueda T.1, Nakanishi H.1, Nakamura T.1, Hongo F.1, Iwata T.2, Kanazawa M.3, Mikami K.4, Kamoi K.1, Okihara K.1, Ukimura O.1

Institutes: 1Kyoto Prefectural University of Medicine, Dept. of Urology, Kyoto, Japan, 2Nantan Hospital, Dept. of Urology, Nantan, Japan, 3Matsushita Memorial Hospital, Dept. of Urology, Moriguchi, Japan, 4Kyoto First Red-Cross Hospital, Dept. of Urology, Kyoto, Japan

211
Decrease in rate of Tx histology after transurethral resection of bladder tumours following implementation of an institutional quality improvement programme

By: Giannarini G., Crestani A., Palumbo V., Calandriello M., Abbinante M., Ficarra V.

Institutes: Academic Medical Centre Hospital Santa Maria Della Misericordia, Dept. of Urology, Udine, Italy

212
White light imaging vs Storz Professional Image Enhancement System (SPIES) cystoscopy during follow up of patients submitted to WLI-transurethral resection of non-muscle-invasive bladder cancer: Preliminary results of a bicenter randomized diagnostic trial

By: Chondros K.1, Kazoulis S.2, Chrysanthakopoulos G.2, Tamiolakis D.3, Kalogeraki A.3, Tzardi M.3, Heretis I.1, Mavromanolakis E.1, Chondros N.1, Zoras O.4, Chalkiadakis G.5, Mamoulakis C.1

Institutes: 1University General Hospital of Heraklion, Dept. of Urology, Heraklion, Greece, 2General Hospital of Chania St. George, Dept. of Urology, Chania, Greece, 3University General Hospital of Heraklion, Dept. of Pathology-Cytopathology, Heraklion, Greece, 4University General Hospital of Heraklion, Dept. of Surgical Oncology, Heraklion, Greece, 5University General Hospital of Heraklion, Dept. of General Surgery, Heraklion, Greece

213
Visualizing the muscularis propria via narrow band imaging during transurethral en bloc dissection for non-muscle-invasive bladder cancer

By: Okada Y., Kawakami S., Takeshita H., Yano A., Chou E., Sugiyama H., Morozumi M., Yamada T.

Institutes: Saitama Medical Center, Dept. of Urology, Saitama, Japan

214
Prognostic significance of markers of systemic inflammatory response in patients with non-muscle invasive bladder cancer

By: Mbeutcha A.1, Shariat S.2, Rieken M.3, Rink M.4, Xylinas E.5, Seitz C.2, Lucca I.6, Mathieu R.7, Rouprêt M.8, Briganti A.9, Karakiewicz P.10, Klatte T.2

Institutes: 1University Hospital of Nice, Dept. of Urology, Nice, France, 2Medical University of Vienna, Dept. of Urology, Vienna, Austria, 3University Hospital of Basel, Dept. of Urology, Basel, Switzerland, 4University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 5Cochin Hospital, APHP, Paris Descartes University, Dept. of Urology, Paris, France, 6Centre Hospitalier Universitaire Vaudois, Dept. of Urology, Lausanne, Switzerland, 7Rennes University Hospital, Dept. of Urology, Rennes, France, 8Pitié- Salpétrière,APHP, University Paris VI, Dept. of Urology, Paris, France, 9Università Vita-Salute, Ospedale S. Raffaele, Dept. of Urology, Milan, Italy, 10University of Montréal, Dept. of Urology, Montréal, Canada

215
A phase II trial of an oral methionine aminopeptidase II (MetAP2) inhibitor for patients with high-risk non-muscle invasive bladder cancer (NMIBC) who relapsed after intravesical therapies: Preliminary results

By: Yao X.2, Wang G.3, Pu J.4, Yao X.5, Zhou F.6, Qi J.7, Ye Z.8, Xie L.9, Chen J.10, Xie K.11, Zhao X.12, Xu Z.13, Guo H.14, Yang Y.15, Cao D.1, Yang B.2, Zhang C.3, Lu Y.4, Du J.5, Ye Y.6, Gu Z.7, Song X.8, Liu B.9, Wen J.10, Deng X.11, Zhong Z.12, Liao G.13, Liu T.14, Zhao Q.15, Jia Y.16, Liu J.17, Pan K.16, Ye D.1

Institutes: 1Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China, 2Shanghai The Tenth People’s Hospital of Tongji University, Dept. of Urology, Shanghai, China, 3The First Affiliated Hospital of Nanchang University, Dept. of Urology, Nanchang, China, 4The First Affiliated Hospital of Soochow University, Dept. of Urology, Suzhou, China, 5Tianjin Medical University Cancer Institute & Hospital, Dept. of Urology, Tianjin, China, 6Sun Yat-Sen University Cancer Center, Dept. of Urology, Guangzhou, China, 7Xin Hua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China, 8Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Dept. of Urology, Wuhan, China, 9The First Affiliated Hospital, Zhejiang University, Dept. of Urology, Hangzhou, China, 10The Second Affiliated Hospital of Zhejiang University School of Medicine, Dept. of Urology, Hangzhou, China, 11Guangzhou The First People’s Hospital, Dept. of Urology, Guangzhou, China, 12The Second Xiangya Hospital of Central South University, Dept. of Urology, Changsha, China, 13Zhejiang Provincial People’s Hospital, Dept. of Urology, Hangzhou, China, 14Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Dept. of Urology, Nanjing, China, 15Beijing Cancer Hospital, Dept. of Urology, Beijing, China, 16Jiangsu Yahong MediTech Co., Ltd., Dept. of Clinical Research, Taizhou, China, 17Jiangsu Yahong MediTech Co., Ltd., Pharmaceutical Sciences, Taizhou, China

216
Discrepancy between guidelines and daily practice in the management of non-muscle-invasive bladder cancer (NMIBC): Results of a European survey

By: Aziz A.2, Bes P.12, Chun F.K2, Dobruch J.3, Kluth L.A2, Gontero P.4, Necchi A.5, Noon A.6, Van Rhijn B.WG7, Rink M.2, Roghmann F.8, Roupret M.9, Seiler R.10, Shariat S.F11, Qvick B.12, Xylinas E.N.1

Institutes: 1Cochin Hospital, Paris Descartes University, Dept. of Urology, Paris, France, 2University Medical Center Hamburg-Eppendorf, Hamburg, Dept. of Urology, Hamburg, Germany, 3Centre of Postgraduate Medical Education, Dept. of Urology, Warsaw, Poland, 4Città Della Salute E Della Scienza Di Torino, Dept. of Urology, Turin, Italy, 5Fondazione IRCCS Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, 6Division of Urology, University of Toronto, Dept. of Urology, Toronto, Canada, 7Netherlands Cancer Institute – Antoni Van Leeuwenhoek Hospital, Dept. of Urology, Amsterdam, The Netherlands, 8Marien Hospital, Ruhr-University Bochum, Dept. of Urology, Herne, Germany, 9Pitié-Salpétrière APHP, Dept. of Urology, Paris, France, 10University of Berne, Dept. of Urology, Berne, Switzerland, 11Medical University of Vienna, Dept. of Urology, Vienna, Austria, 12Ipsen, Dept. of Pharma, Paris, France